P-0127MULTIMODALITY TREATMENT APPROACH FOR LOCALLY ADVANCED PANCREATIC CANCER by Bernhard, Pestalozzi et al.
posters
P 0127 MULTIMODALITY TREATMENTAPPROACH FOR LOCALLY
ADVANCED PANCREATIC CANCER
Pestalozzi Bernhard1, Datta Niloy2, Riesterer Oliver3, De Oliveira Michelle4,
Seifert Burckhardt5, Winder Thomas6, Siebenhuener Alexander1,
Samaras Panagiotis1, Mamot Christoph7, Bodis Stephan2, Clavien Pierre-Alain8
1Department of Oncology, University Hospital of Zurich, Zurich, Switzerland
2Department of Radiation Oncology, Kantonsspital Aarau AG, Aarau, Switzerland
3Department of Radiation Oncology, University Hospital of Zurich, Zurich,
Switzerland
4Department of Surgery, University Hospital of Zurich, Zurich, Switzerland
5Division of Biostatistics, University of Zurich, Zurich, Switzerland
6Department of Oncology, University Hospital of Zurich, Zurich, Switzerland
7Division of Oncology, Kantonsspital Aarau AG, Aarau, Switzerland
8Department of Surgery, University Hospital of Zurich, Zurich, Switzerland
Introduction: Pancreatic cancer is the 7th leading cause of cancer-related death
worldwide with 5-year survival rates of around 5%. Complete surgical resection is the
only curative option but only 10-20% of patients are suitable for it. Probably
micro-metastases at the time of diagnosis are responsible for the poor outcome even
after R0 resection, no nodal involvement (pN0), and despite adjuvant treatment. In the
last decade the prognosis of this illness has not changed much although some
therapeutic improvements have been made. Adjuvant chemotherapy with gemcitabine
had some effect on the one-year survival rate but efficacy is limited. FOLFIRINOX
(5-fluorouracil, oxaliplatin, irinotecan and leucovorin) has become the new standard in
advanced disease. But there is only limited experience with FOLFIRINOX in both the
neoadjuvant as well as the adjuvant setting. Therefore, prospective clinical trials are
needed to investigate the benefit of intensified neoadjuvant and adjuvant
chemotherapy regimens for locally advanced pancreatic cancer (LAPC). In addition,
innovative local treatments like stereotactic body radiotherapy (SBRT), hyperthermia
as well as irreversible electroporation (IRE) have been tried in pancreatic cancer with
some promise. Similarly, these approaches should undergo more formal evaluation.
Based on these considerations the following studies of a tandem approach to LAPC are
being launched.
Methods: Trial Design
Pancreatic cancer resectability is defined by the absence of metastases and only limited
invasion of arteries (SMA, common hepatic artery, celiac trunk) and veins (superior
mesenteric vein / portal vein) (Katz et al. 2013, Ann Surg Oncol 20:2787). Only Stage
III pancreatic cancer (AJCC – TNM 7th edition) will be enrolled in the study. All cases
will be reviewed at the multidisciplinary meeting to confirm eligibility. After obtaining
their informed consent patients will receive 4 cycles of FOLFIRINOX chemotherapy.
Following reassessment, patients without progression will proceed to local treatment.
Diagnostic laparoscopy will be performed to exclude distant metastases. Unresectable
tumors up to 4cm will be randomized between stereotactic body radiotherapy (SBRT)
(Arm A) versus irreversible electroporation (IRE) (Arm B). Tumors larger than 4cm
will be randomized to chemo-radiation (Intensity modulated radiation therapy:
28 × 2Gy = 56 Gy to the primary tumor and metastatic lymph nodes,
28 × 1.8 Gy = 50.4 Gy to the elective nodal area along with gemcitabine 400mg/m2
weekly) (Arm C) versus the same in combination with hyperthermia (weekly
hyperthermia at 41-43°C over 60min, given 24 hours after gemcitabine) (Arm D).
Patients developing metastases or local progression, forbidding continuation of
protocol treatment will go off study at any time. One month following local treatment,
adjuvant chemotherapy with FOLFIRINOX will be resumed for 8 cycles. Statistical
considerations: The expected 1-year survival rate is 50% (p0) and we expect a clinically
relevant difference of +20% (Arms A vs B; Arms C vs. D). Sample size based on
Simon’s two-stage minimax design with one-sided alpha 0.05 and power of 80%,
drop-out rate 10%, is between 24 to 40 per arm; i.e. a total of 96 to 160 patients for the
whole program.
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